Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hexosaminidase D (HEXD) is an enzyme belonging to the glycosyl hydrolase family 20, expressed in humans and predicted to function primarily in the hydrolysis of terminal N-acetylglucosamine (GlcNAc) and N-acetylgalactosamine (GalNAc) residues from cellular substrates, with a preference for galactosaminide. HEXD is related to but distinct from the lysosomal hexosaminidases A (HEXA) and B (HEXB), which are well-characterized in the context of lysosomal storage diseases such as Tay-Sachs and Sandhoff. HEXD is encoded by the HEXD gene (HGNC:26307) and is found in extracellular vesicles. The biological function of HEXD remains less well defined than HEXA/B, but it is considered a candidate for involvement in carbohydrate metabolic pathways and, by homology, lysosomal storage disorders. There are no approved drugs or therapies that specifically target HEXD, and it is not a routinely used disease biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hexosaminidase D (HEXD).